N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide
C16H16ClN7O3 — CID 126678910
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide
N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide (PubChem CID 126678910) has the molecular formula C16H16ClN7O3 and a molecular weight of 389.80 g/mol. Its IUPAC name is N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide.
Molecular Properties
| Compound Name | N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide |
|---|---|
| PubChem CID | 126678910 |
| Molecular Formula | C16H16ClN7O3 |
| Molecular Weight | 389.80 g/mol |
| Exact Mass | 389.10 |
| IUPAC Name | N-(2-amino-2-oxoethyl)-3-[(5-amino-2H-triazolo[4,5-b]pyridin-7-yl)oxymethyl]-4-chloro-N-methylbenzamide |
| SMILES | CN(CC(N)=O)C(=O)c1ccc(Cl)c(COc2cc(N)nc3n[nH]nc23)c1 |
| InChI | InChI=1S/C16H16ClN7O3/c1-24(6-13(19)25)16(26)8-2-3-10(17)9(4-8)7-27-11-5-12(18)20-15-14(11)21-23-22-15/h2-5H,6-7H2,1H3,(H2,19,25)(H3,18,20,21,22,23) |
| InChIKey | GYWDAGIRXANHQY-UHFFFAOYSA-N |
| XLogP | 0.72 |
| TPSA | 153.11 Ų |
| H-Bond Donors | 3 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 389.80 |
| LogP ≤ 5 | 0.72 |
| H-Bond Donors ≤ 5 | 3 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 126678910 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.